Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Kairos Therapeutics

Kairos Therapeutics
2013 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
Description

Developer of antibody-drug conjugate therapeutics for cancer. The company provides an antibody-drug conjugate platform that enables development of therapeutics for the treatment of multiple forms of cancer.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Acquirer
Primary Office
  • 2405 Wesbrook Mall
  • Fourth Floor
  • Vancouver, British Columbia V6T 1Z3
  • Canada
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kairos Therapeutics’s full profile, request a free trial.

Kairos Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 22-Mar-2016 Completed Startup
1. Early Stage VC 12-Dec-2013 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Kairos Therapeutics Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ADC Biotechnology Venture Capital-Backed Chester, United Kingdom 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000 00000000000 Private Equity-Backed Abingdon, United Kingdom 00 000.00 0000000 0000 000.00
0000000 000 Formerly PE-Backed Cambridge, MA 000 000000&0
0000000 Formerly PE-Backed Beijing, China 0000 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

Kairos Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
CDRD Ventures Corporate Venture Capital Minority 000 0000 000000 0

Kairos Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
John Babcook Co-Founder, Chief Scientific Officer & President